Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Fano

10 clinical trials in Fano, Italy. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Fano at a glance
10
clinical trials
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

10 trials in Fano

Open in trial search

Colitis ulcerative

Recruiting

Study on Eltrekibart and Mirikizumab for Adults with Moderate to Severe Ulcerative Colitis

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Mirikizumab
  • Sponsor:Eli Lilly & Co.

Oesophageal adenocarcinoma

Recruiting

Switch maintenance with paclitaxel, ramucirumab and tislelizumab versus continued chemotherapy with tislelizumab in HER2‑negative, PD‑L1‑positive gastroesophageal cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Fondazione GONO G.I.

Squamous cell carcinoma of lung+4

Recruiting

A study of PF-08634404 and sigvotatug vedotin in patients with advanced solid tumors

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Sigvotatug vedotin
  • Sponsor:Pfizer Inc.

Squamous cell carcinoma of lung+4

Recruiting

A study of PF-08634404 and a drug combination in adults with advanced or metastatic non-small cell lung cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Pfizer Inc.

Non-small cell lung cancer

Recruiting

A Study of Telisotuzumab Adizutecan Compared to Standard Treatment in Adults with Advanced Non-Small Cell Lung Cancer After Previous Treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Non-small cell lung cancer+1

Recruiting

Study of trastuzumab deruxtecan with pembrolizumab versus platinum chemotherapy with pembrolizumab for patients with untreated HER2-positive non-small cell lung cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Daiichi Sankyo Inc.

Non-small cell lung cancer stage IV

Recruiting

Study on the Effectiveness and Safety of Carboplatin, Pemetrexed, and Lorlatinib for ALK Positive Non-Small Cell Lung Cancer with Extracranial Progression

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Centro Di Riferimento Oncologico Di Aviano

Study of setidegrasib (ASP3082) and docetaxel in patients with KRAS G12D‑mutated advanced/metastatic NSCLC after platinum chemo and checkpoint inhibitor

Not yet recruiting
Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:ASP3082
  • Sponsor:Astellas Pharma Global Development Inc.

Breast cancer

Not recruiting

Study on Chemotherapy and Aromatase Inhibitors (Exemestane, Letrozole, Anastrozole) for Post-Menopausal Patients with Early Breast Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:IRCCS Ospedale Policlinico San Martino

Triple negative breast cancer

Not recruiting

Study on Avelumab for Patients with High-Risk Triple Negative Breast Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Avelumab
  • Sponsor:Universita Degli Studi Di Padova

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Fano

What the registry says about research in the country

01 Gastroenterology Research

Innovative clinical trials focusing on Ulcerative Colitis treatments, investigating new therapeutic approaches using targeted biological agents for inflammatory bowel conditions.

  • Treatment efficacy evaluation
  • Novel therapeutic combinations
  • Remission induction studies

Research aims to advance treatment options for patients with moderate to severe disease activity.

02 Oncology Studies

Comprehensive research in breast cancer treatment, particularly focusing on endocrine-responsive early-stage cases in post-menopausal patients.

  • Chemotherapy optimization
  • Endocrine therapy integration
  • Treatment timing strategies

Studies explore optimal treatment sequences to prevent disease recurrence and improve patient outcomes.

03 Treatment Integration Research

Advanced studies examining the concurrent versus sequential administration of different treatment modalities in cancer care.

  • Treatment synchronization
  • Therapeutic timing
  • Clinical efficacy assessment

Research focuses on determining optimal treatment schedules for enhanced therapeutic effectiveness.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.